Fibromyalgia is a chronic pain syndrome that affects about 2% of the U.S. general population, with greater prevalence among women (3.5%) than men (0.5%). Previous research results suggest that the experience of pain (allodynia) upon sphygmomanometry may indicate the presence of fibromyalgia.
The aim of this study was to confirm these findings in patients with fibromyalgia and other chronic pain conditions and evaluate the use of sphygmomanometry as a potential screening tool for the identification of patients with fibromyalgia.
A total of 150 people participated in this multicenter, cross-sectional observational study. The study included a physician-conducted evaluation to determine if the participant met the American College of Rheumatology (ACR) 1990 diagnostic criteria for fibromyalgia. The presence of sphygmomanometry-evoked allodynia was assessed during a seated cuff pressure inflation that was repeated three times on each arm. Each site was provided a sphygmomanometer to ensure standardization, and the pressure of the cuff at the moment of pain initiation was recorded. If the patient did not indicate pain prior to 180 mmHg, then the inflation was stopped, a notation of no pain was made, and a cuff pressure of 180 mmHg was recorded. The mean of the six cuff pressure measurements was used for the analyses. Logistic regression was performed to analyze the relationship between sphygmomanometry-evoked allodynia and fibromyalgia.
The evaluable sample was 148 (one participant had too large an arm circumference for the sphygmomanometer and another did not receive the clinician evaluation of ACR-determined fibromyalgia diagnosis). Over half of the participants were determined to have an ACR diagnosis of fibromyalgia. Of these, 71 (91%) were women and had an average age of 54 years. Of the 70 participants with no fibromyalgia diagnosis, 42 (60%) were women and also had an average age of 54 years. Sixty-one (78%) of the fibromyalgia participants, compared with 25 (36%) of those with no fibromyalgia diagnosis, reported sphygmomanometry-evoked allodynia. The participants with fibromyalgia reported pain ata lower cuff pressure compared with those without fibromyalgia (132 mmHg vs. 166 mmHg, p < .01). The logistic regression showed that sphygmomanometry-evoked allodynia predicted an ACR-determined FM diagnosis (χ2 = 19.4, p < .01).
These findings support previous research suggesting that patients who report pain upon sphygmomanometry may warrant further evaluation for the presence of fibromyalgia.
Arthi B. Chandran, MS, MPH, is Associate Director, Global Health Economics and Outcomes Research, Pfizer, Inc., New York, New York.
Cheryl D. Coon, PhD, is Director of Psychometrics; Susan A. Martin, MSPH, is Senior Director of Patient Reported Outcomes; Lori D. McLeod, PhD, is Head of Psychometrics; and Theresa M. Coles, MS, is Senior Health Outcomes Analyst, Patient Reported Outcomes, RTI Health Solutions, Durham, North Carolina.
Lesley M. Arnold, MD, is Professor of Psychiatry and Behavioral Neuroscience and Director of Women’s Health Research Program, College of Medicine, University of Cincinnati, Ohio.
Accepted for publication April 5, 2012.
The authors would like to thank all of the patients that participated in the study and the principal investigators at each site, namely, Drs. Ara Dikranian, Christopher Gilmore, Theresa Lawrence-Ford, Wonil Lee, Michael McNett, Yvonne Sherrer, Dana Trotter, and Alvin Wells. The authors also thank the following individuals at RTI Health Solutions: Laurie Zografos, Carolyn Sweeney, and Paul Shannon.
The study was funded by Pfizer, and employees of Pfizer were involved in the review of the protocol, statistical analysis plan, and results of the research.
Ms. Chandran is employed by Pfizer. Ms. Martin, Dr. Coon, Dr. McLeod, and Ms. Coles are employees of RTI Health Solutions, who were paid consultants to Pfizer in connection with the development of this research and development of this manuscript. Dr. Arnold has received consulting fees from Astra Zeneca, Cypress Bioscience, Inc., Eli Lilly and Company, Forest Laboratories, Inc., Grunenthal, Johnson & Johnson, Sanofi Aventis, and Takeda (less than $10,000 each) and from Pfizer, Inc. (more than $10,000) and research support from Boehringer Ingelheim, Cypress Bioscience, Inc., Eli Lilly and Company, Forest Laboratories, Inc., Novartis, and Pfizer, Inc.
Corresponding author: Arthi B. Chandran, MS, MPH, Pfizer, Inc., 235 East 42nd Street, New York, NY 10017 (e-mail: Arthi.B.Chandran@pfizer.com).